No Data
No Data
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough
We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Express News | Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7
No Data